Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases

Reuters10-24

<a href="https://laohu8.com/S/SYRE">Spyre Therapeutics</a> Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases

Spyre Therapeutics Inc. announced new scientific presentations at the upcoming American College of Rheumatology $(ACR)$ Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577137245?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577137245","market":"fut","top_or_hot":-1,"title":"Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a> Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced new scientific presentations at the upcoming American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-24 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a> Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced new scientific presentations at the upcoming American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYRE","symbol_name":"SPYRE THERAPEUTICS INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDLmMH4j:1","article_id":"2577137245","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577137245","pubTimestamp":1761307226,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spyre Therapeutics Inc. announced new scientific presentations at the upcoming American College of Rheumatology  Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelli","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYRE":"SPYRE THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Spyre Therapeutics报告抗TL1A抗体SPY072治疗风湿性疾病的6个月1期阳性数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYRE":0.9},"content_text":"Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases\n    \n\n        Spyre Therapeutics Inc. announced new scientific presentations at the upcoming American College of Rheumatology $(ACR)$ Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550156-en) on October 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577137245","isCrawlerRequest":true}